Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 5
1976 11
1977 16
1978 17
1979 23
1980 27
1981 16
1982 24
1983 16
1984 14
1985 17
1986 15
1987 12
1988 9
1989 13
1990 9
1991 6
1992 7
1993 8
1994 13
1995 3
1996 4
1997 2
1998 5
1999 6
2000 4
2001 1
2002 4
2003 2
2005 1
2006 2
2007 2
2008 3
2009 1
2012 3
2013 2
2014 1
2016 2
2018 2
2019 4
2020 10
2021 23
2022 21
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

403 results

Results by year

Filters applied: . Clear all
Page 1
Viloxazine.
[No authors listed] [No authors listed] 2023 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Jan 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 36701514 Free Books & Documents. Review.
There is no published experience with viloxazine during breastfeeding. If viloxazine is required by the mother of an older infant, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially w …
There is no published experience with viloxazine during breastfeeding. If viloxazine is required by the mother of an older inf …
Viloxazine.
[No authors listed] [No authors listed] 2021 Aug 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. 2021 Aug 20. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012–. PMID: 34542988 Free Books & Documents. Review.
Viloxazine is a selective norepinephrine reuptake inhibitor that is used in the therapy of attention deficit/hyperactivity disorder in children. Viloxazine has been associated with uncommon and mild serum enzyme elevations during therapy but not with occurrence of c …
Viloxazine is a selective norepinephrine reuptake inhibitor that is used in the therapy of attention deficit/hyperactivity disorder i …
Viloxazine: Pediatric First Approval.
Lamb YN. Lamb YN. Paediatr Drugs. 2021 Jul;23(4):403-409. doi: 10.1007/s40272-021-00453-3. Paediatr Drugs. 2021. PMID: 34036533 Free PMC article. Review.
Viloxazine is available as extended-release capsules for once-daily oral administration. This article summarizes the milestones in the development of viloxazine leading to this first pediatric approval for ADHD....
Viloxazine is available as extended-release capsules for once-daily oral administration. This article summarizes the milestones in th …
Viloxazine.
Mathew BM, Pellegrini MV. Mathew BM, et al. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 35015448 Free Books & Documents.
Viloxazine was marketed as an antidepressant in Europe for more than 2 decades under an immediate-release formulation before its potential as a treatment for patients with attention-deficit hyperactivity disorder (ADHD) was considered. Viloxazine received its first …
Viloxazine was marketed as an antidepressant in Europe for more than 2 decades under an immediate-release formulation before its pote …
Viloxazine in the Treatment of Attention Deficit Hyperactivity Disorder.
Edinoff AN, Akuly HA, Wagner JH, Boudreaux MA, Kaplan LA, Yusuf S, Neuchat EE, Cornett EM, Boyer AG, Kaye AM, Kaye AD. Edinoff AN, et al. Front Psychiatry. 2021 Dec 17;12:789982. doi: 10.3389/fpsyt.2021.789982. eCollection 2021. Front Psychiatry. 2021. PMID: 34975586 Free PMC article. Review.
With the support of four phase 3 studies involving more than 1,000 pediatric patients 6-17 years old, the FDA has approved the non-stimulant, serotonin-norepinephrine modulating agent (SNMA) viloxazine in an extended-release capsule (viloxazine ER) for treatment of …
With the support of four phase 3 studies involving more than 1,000 pediatric patients 6-17 years old, the FDA has approved the non-stimulant …
Viloxazine Hydrochloride.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2021 Aug 30;78(17):1544-1547. doi: 10.1093/ajhp/zxab231. Am J Health Syst Pharm. 2021. PMID: 34136905 No abstract available.
Extended-Release Viloxazine for the Treatment of Attention-Deficit Hyperactivity Disorder in School-Age Children and Adolescents.
Raible H, D'Souza MS. Raible H, et al. Ann Pharmacother. 2023 Dec;57(12):1436-1448. doi: 10.1177/10600280231163252. Epub 2023 Apr 5. Ann Pharmacother. 2023. PMID: 37021356 Review.
OBJECTIVE: To describe the efficacy and safety of extended-release viloxazine (viloxazine ER; Qelbree) for the treatment of attention-deficit hyperactivity disorder (ADHD) in school-age children and adolescents (6-17 years). ...Like atomoxetine, viloxazine ER …
OBJECTIVE: To describe the efficacy and safety of extended-release viloxazine (viloxazine ER; Qelbree) for the treatment of at …
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder.
Nasser A, Hull JT, Chaturvedi SA, Liranso T, Odebo O, Kosheleff AR, Fry N, Cutler AJ, Rubin J, Schwabe S, Childress A. Nasser A, et al. CNS Drugs. 2022 Aug;36(8):897-915. doi: 10.1007/s40263-022-00938-w. Epub 2022 Jul 27. CNS Drugs. 2022. PMID: 35896943 Free PMC article. Clinical Trial.
Recent phase III trials have demonstrated the efficacy and safety of viloxazine extended-release capsules (viloxazine ER; Qelbree()) in pediatrics (6-17 years of age). ...Due to these positive results, the US FDA recently approved viloxazine ER to treat adult …
Recent phase III trials have demonstrated the efficacy and safety of viloxazine extended-release capsules (viloxazine ER; Qelb …
Viloxazine extended-release capsules for the treatment of attention-deficit/ hyperactivity disorder in adult patients.
Childress A, Sottile R, Khanbijian S. Childress A, et al. Expert Rev Neurother. 2023 Jul-Dec;23(11):945-953. doi: 10.1080/14737175.2023.2265068. Epub 2023 Oct 27. Expert Rev Neurother. 2023. PMID: 37846759 Review.
Only one nonstimulant, atomoxetine, was available for the treatment of ADHD in adults until recently. In April 2022, a second nonstimulant, viloxazine extended-release (VLX-ER), became available in the US for the treatment of adult ADHD. ...
Only one nonstimulant, atomoxetine, was available for the treatment of ADHD in adults until recently. In April 2022, a second nonstimulant, …
Viloxazine in the Management of CNS Disorders: A Historical Overview and Current Status.
Findling RL, Candler SA, Nasser AF, Schwabe S, Yu C, Garcia-Olivares J, O'Neal W, Newcorn JH. Findling RL, et al. CNS Drugs. 2021 Jun;35(6):643-653. doi: 10.1007/s40263-021-00825-w. Epub 2021 May 18. CNS Drugs. 2021. PMID: 34003459 Free PMC article. Review.
In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was associated with a relatively low risk for cardiotoxicity. Gastrointestinal symptoms were the most commonly reported side effects. The therapeutic …
In contrast to first-generation antidepressants (e.g., tricyclic antidepressants, monoamine oxidase inhibitors), viloxazine was assoc …
403 results